Lonsurf | Trifluridine and Tipiracil (download only)

Regular price $0.00

At what stage is this treatment used?

  • Treatment of adult patients with metastatic bowel cancer (mCRC) who have been previously treated with, or are not considered candidates for fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents

Is this drug available via the Pharmaceutical Benefits Scheme (PBS) as a subsidised treatment?

Yes, subject to the following criteria: 
    Initial treatment for patients with metastatic bowel cancer.

    • Patient must have a WHO performance status of 1 or less;

      AND
    • Patient must have previously received treatment with fluoropyrimidine, oxaliplatin, irinotecan-based chemotherapies, an anti-vascular endothelial growth factor (anti-VEGF) agent and an anti-epidermal growth factor receptor (anti-EGFR) agent for this condition; OR
      • Patient must not be a suitable candidate for treatment with fluoropyrimidine, oxaliplatin, irinotecan-based chemotherapies, an anti-VEGF agent and an anti-EGFR agent for this condition;

        AND
        • The treatment must be the sole PBS-subsidised therapy for this condition.
          Continuing treatment for metastatic bowel cancer
            • Patient must have previously been treated with PBS-subsidised treatment with this drug for this condition;

              AND
              • Patient must not develop progressive disease whilst receiving PBS-subsidised treatment with this drug for this condition;

                AND
                • The treatment must be the sole PBS-subsidised therapy for this condition.